Research and Development Expenses |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||
| Research and Development Expenses | |||||||||||||||||||||||||||||||||||||||||
| Research and Development Expenses | 15. Research and Development Expenses Research and development expenses are summarized as follows:
Research and development expenses include expenditures for collaborative arrangements under ASC 808 to evaluate the combination of the Group’s drug compounds with the collaboration partners’ drug compounds. For the six months ended June 30, 2026 and 2025, the Group has incurred US$6.3 million and US$3.2 million respectively, related to such collaborative arrangements. Note: Personnel compensation and related costs mainly included clinical and regulatory, discovery, chemistry, manufacturing and controls functions. A portion of these costs are absorbed in inventory costs based on commercial production and are not included in research and development expenses. |
||||||||||||||||||||||||||||||||||||||||